SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot

Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1...

Descripción completa

Detalles Bibliográficos
Autores principales: Achtnichts, Lutz, Ovchinnikov, Arkady, Jakopp, Barbara, Oberle, Michael, Nedeltchev, Krassen, Fux, Christoph Andreas, Sellner, Johann, Findling, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875864/
https://www.ncbi.nlm.nih.gov/pubmed/35214799
http://dx.doi.org/10.3390/vaccines10020341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875864/
https://www.ncbi.nlm.nih.gov/pubmed/35214799
http://dx.doi.org/10.3390/vaccines10020341

Ejemplares similares